AIM ImmunoTech Inc. Overview
Pro stress-test →AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. The company's flagship asset is Ampligen (rintatolimod), a double-stranded RNA immunomodulator currently in Phase 2 development for pancreatic cancer in combination with AstraZeneca's Imfinzi, with recent mid-year data showing positive therapeutic effects across multiple cancer types.
Strategic Profile
Pro stress-test →AIM is positioned in the competitive immunotherapy space with a differentiated mechanism targeting TLR3 agonism. The company is advancing combination therapy approaches for oncology while maintaining legacy products like Alferon N Injection, though current revenue generation remains minimal as the company operates in clinical-stage development mode.
Competitive Landscape
Pro stress-test →AIM competes in crowded immuno-oncology space against companies like Ayala Pharmaceuticals, Immunocore Holdings, and ImmunityBio. Primary differentiation comes from TLR3-targeted mechanism and combination therapy approach, though Ampligen faces typical development-stage competition from better-capitalized players with more advanced pipeline stages.
Industry Context
AIM ImmunoTech Inc. operates in Biotechnology / Immuno-Oncology / Immunotherapy.
Key facts
Headquarters: Ocala, Florida · Revenue: $112K · Market cap: $3.74M